New Zealand markets closed

ABBV Nov 2024 220.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.78000.0000 (0.00%)
At close: 11:07AM EDT
Full screen
Previous close0.7800
Open0.8100
Bid0.0000
Ask0.9900
Strike220.00
Expiry date2024-11-15
Day's range0.7800 - 0.8100
Contract rangeN/A
Volume2
Open interest418
  • PR Newswire

    AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

    AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcome

  • Zacks

    AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors

    The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.

  • GuruFocus.com

    AbbVie Inc's Dividend Analysis

    AbbVie Inc (NYSE:ABBV) recently announced a dividend of $1.55 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-12. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into AbbVie Inc's dividend performance and assess its sustainability.